Ultragenyx Pharmaceutical Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical or view top-rated stocks.

12 equities research analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their RARE stock forecasts range from $73.00 to $162.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $111.29 in the next twelve months. This suggests a possible upside of 83.7% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical or view top-rated stocks among Wall Street analysts.

Ultragenyx Pharmaceutical's stock was trading at $84.09 at the beginning of the year. Since then, RARE shares have decreased by 28.0% and is now trading at $60.57.
View the best growth stocks for 2022 here.

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.76) by $0.43. The biopharmaceutical company earned $79.94 million during the quarter, compared to the consensus estimate of $84.25 million. Ultragenyx Pharmaceutical had a negative net margin of 141.65% and a negative trailing twelve-month return on equity of 49.18%. Ultragenyx Pharmaceutical's quarterly revenue was down 19.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.03) EPS.
View Ultragenyx Pharmaceutical's earnings history.

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

Some companies that are related to Ultragenyx Pharmaceutical include UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Elanco Animal Health (ELAN), Jazz Pharmaceuticals (JAZZ), Dr. Reddy's Laboratories (RDY), Organon & Co. (OGN), Teva Pharmaceutical Industries (TEVA), Legend Biotech (LEGN), Grifols (GRFS) and Maravai LifeSciences (MRVI).
View all of RARE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Ultragenyx Pharmaceutical's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.53%), Federated Hermes Inc. (5.70%), BlackRock Inc. (4.96%), Wellington Management Group LLP (4.82%), Capital International Investors (4.78%) and Clearbridge Investments LLC (4.10%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical.

RARE stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, Invesco Ltd., Bank of New York Mellon Corp, Emerald Mutual Fund Advisers Trust, Capital Group International Inc. CA , BlackRock Inc., Capital International Ltd. CA, and Citigroup Inc.. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last two years include Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg, and William Aliski.
View insider buying and selling activity for Ultragenyx Pharmaceutical or view top insider-selling stocks.

RARE stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, State Street Corp, Rock Springs Capital Management LP, Dimensional Fund Advisors LP, Peregrine Capital Management LLC, International Biotechnology Trust PLC, Verition Fund Management LLC, and Verition Fund Management LLC.
View insider buying and selling activity for Ultragenyx Pharmaceutical or or view top insider-buying stocks.

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RARE stock can currently be purchased for approximately $60.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $4.24 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454.02 million in net income (profit) each year or ($6.87) on an earnings per share basis.

Ultragenyx Pharmaceutical employs 1,119 workers across the globe.

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at [email protected], or via fax at 415-483-8810.